Clinical Trial

A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression

Study acronym: NSCLC， YAP
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of Chidamide in combination with Ivonescimab in the treatment of advanced non-small cell lung cancer with secondary immune resistance and high YAP protein expression.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-05-09
Trial Details
NCT Number NCT07412262
Lead Sponsor Guangdong Association of Clinical Trials
Collaborators: Innovent Biologics, Inc., Akesobio
Conditions Non-Small Cell Lung Cancer
Enrollment 32 participants
Start Date 2026-05-15
Primary Completion 2028-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08